研發(fā)產(chǎn)品
| 名稱 Name |
CAS | 適應(yīng)癥 Treatment |
|---|---|---|
| Arbidol | 131707-25-0 | Double-effect anti-influenza various drug |
| 阿比洛爾 | 由A、B型流感病毒引起的上呼吸道感染 | |
| Anamorelin Hydrochloride | 861998-00-7 | Cancer cachexia |
| 鹽酸阿拉莫林 | 癌癥惡病質(zhì) | |
| Tirzepatide | 2023788-19-2 | Type 2 diabetes mellitus |
| 替爾泊肽 | II型糖尿病 | |
| Bazedoxifene | 198481-32-2 | Post–menopausalosteoporosis |
| 巴多昔芬 | 骨質(zhì)疏松癥 | |
| Sitagliptin | 486460-32-6 | Type 2 diabetes |
| 西格列汀 | 2 型糖尿 | |
| (R)-Lansoprazole | 138530-94-6 | Antipeptic ulcer medicine |
| 右旋蘭索拉唑 | 抗消化性潰瘍藥 | |
| Eltrombopag | 496775-61-2 | Thrombocytopenia in patients with chronic ITP |
| 艾曲泊帕 | 慢性丙型肝炎(CHC)患者血小板減少癥 | |
| Larotrectinib | 1223403-58-4 | entity tumor |
| 拉曲替尼 | 實體瘤 | |
| Baloxavir | 1985605-59-1 | Influenza A and B viruses |
| 巴洛沙韋 | 甲型、乙型流感病毒 | |
| Cenicriviroc | 497223-25-3 | Nonalcoholic Steatohepatitis (NASH) |
| 成人非酒精性脂肪性肝炎 | ||
| Sermaglutide | 910463-68-2 | Type 2 diabetes mellitus |
| 索馬魯肽 | II型糖尿病 | |
| Entrectinib | 1108743-60-7 | Entity tumor |
| 恩曲替尼 | 實體瘤 | |
| Relugolix | 737789-87-6 | Prostate cancer, uterine fibroids |
| 瑞盧戈利 | 前列腺癌、子宮肌瘤 | |
| Linaclotide | 851199-59-2 | Irritable bowel syndrome |
| 利那洛肽 | 腸易激綜合征 | |
| Choline Fenofibrate | 856676-23-8 | Hyperlipidemia control |
| 非諾貝特酸膽堿 | 高血脂控制 | |
| Nerinetide | 500992-11-0 | Neuroprotection in patients with ischemic stroke |
| 尼瑞奈肽 | 缺血性腦卒中患者神經(jīng)保護 | |
| Difelikefalin | 1024828-77-0 | Chronic kidney disease associated pruritus (CKD AP) in adults undergoing hemodialysis |
| 地非法林 | 用于治療接受血液透析的成年人中重度慢性腎病相關(guān)瘙癢（CKD aP） |
關(guān)于立新
創(chuàng)新與國際化
產(chǎn)品與服務(wù)
可持續(xù)發(fā)展
立新動態(tài)
加入我們
聯(lián)系我們
